Mar 31, 2026 6:40am EDT SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mar 04, 2026 4:20pm EST SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
Feb 26, 2026 8:23am EST SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
Jan 28, 2026 8:00am EST SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
Jan 21, 2026 8:00am EST SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
Dec 22, 2025 8:00am EST SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Nov 17, 2025 10:15am EST Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
Nov 05, 2025 4:20pm EST SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
